Sterling Capital Management
PRLD icon

Sterling Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Sterling Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.56K Buy
911
+814
+839% +$3.99K ﹤0.01% 3003
2026
Q2 		$517 Buy
+97
New +$422 ﹤0.01% 3218
2025
Q2 		– Sell
-227
Closed -$174 – 3361
2025
Q1 		$174 Buy
227
+185
+440% +$173 ﹤0.01% 3100
2024
Q4 		$54 Hold
42
– – ﹤0.01% 3209
2024
Q3 		$87 Buy
+42
New +$195 ﹤0.01% 3203

Other funds holding PRLD

Empirical Wealth Management
Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Sterling Capital Management's PRLD Position: Q3 2026 in Review

Sterling Capital Management increased its Prelude Therapeutics (PRLD) stake by 839% in Q3 2026, buying an estimated $3.99K and bringing the position to 911 shares worth $3.56K. The position accounts for ﹤0.01% of the portfolio, ranked #3003.

Sterling Capital Management first reported a position in PRLD in Q3 2024 and has held it in 5 quarters since. 7 funds tracked by Wall St. Rank hold PRLD as of Q3 2026.

  • Sterling Capital Management held 911 shares of Prelude Therapeutics worth $3.56K as of Q3 2026.
  • Sterling Capital Management bought 814 Prelude Therapeutics shares in Q3 2026, an estimated $3.99K.
  • Prelude Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #3003 holding.
  • Sterling Capital Management first reported a position in Prelude Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 7 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.